Semmelweis Study Links 6%-28% of Hard-to-Treat Arthritis Cases to Non-Inflammatory Drivers
Updated
Updated · SciTechDaily · Jun 7
Semmelweis Study Links 6%-28% of Hard-to-Treat Arthritis Cases to Non-Inflammatory Drivers
1 articles · Updated · SciTechDaily · Jun 7
Summary
Semmelweis University researchers say persistent rheumatoid arthritis pain and fatigue can continue even after inflammation is controlled, with sleep disorders, depression, obesity and smoking helping sustain symptoms.
Two 2026 papers in Nature Reviews Rheumatology and The Lancet Rheumatology outline a model that uses treat-to-target monitoring as an early warning system when clinical targets improve but patients still feel unwell.
Pain, depression, poor sleep and reduced activity can reinforce one another, the team said, creating cycles that worsen daily functioning and can prompt unnecessary medication escalation if the root cause is missed.
An estimated 6% to 28% of rheumatoid arthritis patients fall into the difficult-to-treat category, and the researchers said earlier identification of non-inflammatory drivers could improve outcomes and doctor-patient relationships.
The group said its framework has drawn broad international uptake, with related publications cited more than 1,000 times, and it is now exploring AI tools to identify patient subgroups for more personalized treatment.
AI promises personalized arthritis care, but can it overcome inherent biases to treat all patients equitably?
Your arthritis inflammation is gone, but the pain remains. Could the hidden cause be your lifestyle and mental health?
Beyond Inflammation: Semmelweis University’s Breakthrough in Managing Difficult-to-Treat Rheumatoid Arthritis with Multidisciplinary and AI Solutions
Overview
Rheumatoid arthritis (RA) is a chronic autoimmune disease where the immune system attacks the joints, causing pain, swelling, and stiffness. While most patients respond to standard treatments, a significant group—called difficult-to-treat (D2T) RA—continues to suffer despite ongoing therapy. Semmelweis University’s recent breakthrough identified non-inflammatory drivers as key contributors to these persistent symptoms. This discovery is changing how D2T RA is understood and managed, moving beyond just treating inflammation. The new approach focuses on a broader range of factors, aiming for more effective and personalized care for patients who do not respond to conventional treatments.